Drugs / Amph-Peptides 7P
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05726864 | Apr 2023 → Apr 2026 overdue | colorectal cancer, pancreatic ductal adenocarcinoma | Elicio Therapeutics | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07083479 | — | pancreatic ductal adenocarcinoma | Elicio Therapeutics | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amph-Peptides 7P | “ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during...” NCT05726864 ↗1“ELI-002 Amph-CpG-7909 (10.0 mg) admixed with ELI-002 Amph-Peptides 7P (4.9 mg)” NCT07083479 ↗ |
| Modality | Peptide | “a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]” NCT05726864 ↗ |
| Route | Subcutaneous | “administered via SC injection” NCT07083479 ↗ |